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Abstract
Cardiovascular disease (CVD) is the leading cause of death in renal transplant recipients (RTR). Elevated plasma asym-
metric dimethylarginine (pADMA), an endogenous nitric oxide synthase inhibitor produced from the turnover of methylated 
arginine moieties in proteins, is a risk factor for CVD and mortality. It is unknown how urinary ADMA excretion (uADMA), 
one of the main ADMA elimination routes, is associated with long-term survival. Furthermore, the association of pADMA 
and uADMA with markers for turnover of arginine-methylated proteins is unknown. We analyzed ADMA using a validated 
GC–MS/MS method in plasma and 24-h urine samples of 685 RTR, included ≥ 1 year after transplantation. We also ana-
lyzed urine symmetric dimethylarginine (uSDMA) using the same method. Urinary creatinine and urea excretions were 
used as markers for turnover of muscle protein and amino acids, respectively. We applied Cox regression analyses to study 
associations of pADMA, uADMA, and uSDMA with all-cause and CVD mortality. Mean pADMA was 0.61 ± 0.12 µM, 
uADMA was 31 ± 13 µmol/24 h, and uSDMA was 52 ± 19 µmol/24 h. Over median follow-up of 5.4 [4.9–6.1] years, 147 
RTR died, of which 58 (39%) from CVD. High pADMA was associated with high all-cause mortality (HR per SD [95% 
CI]: 1.45 [1.26–1.67], P < 0.001), while high uADMA was associated with low all-cause and CVD mortality (HR per SD 
[95% CI]: 0.57 [0.47–0.69], P < 0.001, and 0.55 [0.40–0.74], P < 0.001, respectively). The associations were independent 
of adjustment for potential confounders. Creatinine excretion was associated with both pADMA (st. β:− 0.21, P = 0.003) 
and uADMA (st. β: 0.49, P < 0.001), and urea excretion was associated with uADMA (st. β: 0.56, P < 0.001). Associations 
of uSDMA with outcomes and with creatinine excretion and urea excretion were comparable to those of uADMA. The 
associations of pADMA, uADMA and uSDMA with mortality were strongly affected by adjustment for creatinine excretion 
and urea excretion. We found for the first time that high uADMA and high uSDMA are associated with less risk of all-cause 
and CVD mortality. The links of uADMA and uSDMA with markers of muscle protein and amino acid turnover may serve 
to further understand ADMA and SDMA homeostasis and their clinical implications.
Keywords Kidney transplantation · ADMA · SDMA · Muscle mass · Protein turnover · Long-term survival
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HR  Hazard ratio
IQR  Interquartile range
L-NAME  NG-Nitro-l-arginine methyl ester
mGFR  Measured glomerular filtration rate
MMA  Monomethylated arginine
mTOR  Mammalian target of rapamycin
NOS  Nitric oxide synthase
pADMA  Plasma asymmetric dimethylarginine
PRMT  Protein arginine N-methyltransferase
RTR  Renal transplant recipient
SDMA  Symmetric dimethylarginine
uADMA  Urinary asymmetric dimethylarginine
uSDMA  Urinary symmetric dimethylarginine
Introduction
Cardiovascular disease (CVD) is the leading cause of death 
in renal transplant recipients (RTR). With the increasing 
number of transplantations and people living with a renal 
transplant (Saran et al.  2018), it is of particular importance 
to find population-specific risk factors for cardiovascular dis-
ease and mortality. Asymmetric dimethylarginine (ADMA) 
is an endogenous nitric oxide synthase (NOS) inhibitor and 
produced from the turnover of arginine-methylated proteins 
(Teerlink 2005). High plasma ADMA (pADMA) is consid-
ered a risk factor for premature mortality and cardiovascu-
lar disease in the general population, patients with chronic 
kidney disease, and RTR (Zoccali et al. 2001, 2002; Achan 
et al. 2003; Wolf et al. 2012; Frenay et al. 2015). Since renal 
excretion of ADMA is one of the main ways of its elimina-
tion and pADMA concentrations increase with worse renal 
function, ADMA is considered a uremic toxin (Kielstein and 
Zoccali 2005; Jacobi and Tsao 2008). Urinary ADMA excre-
tion (uADMA) is, therefore, an interesting, yet understudied 
component of ADMA homeostasis. In RTR, it is unknown 
how uADMA is associated with long-term outcomes and 
how pADMA and uADMA influence each other’s associa-
tion with long-term outcomes. Furthermore, it is unknown 
how ADMA is associated with markers for its production 
from the turnover of arginine-methylated protein sources.
We aimed to study pADMA and 24-h uADMA, and their 
potential associations with all-cause and cardiovascular 
mortality in a large prospective cohort of stable RTR after 
transplantation. Second, in a sub-population, we aimed to 
study the association of pADMA and uADMA with mark-
ers of protein turnover: urinary creatinine excretion and uri-
nary urea excretion, reflecting turnover of muscle and amino 
acids, respectively (Maroni et al. 1985; Wyss and Kaddurah-
Daouk 2000), while adjusting for differences in true glo-
merular filtration rate (GFR). In addition to our analyses 
for the urinary excretion of ADMA, we performed analyses 
for the urinary excretion of symmetric dimethylarginine 
(uSDMA). Symmetric dimethylarginine (SDMA) is an iso-
mer of ADMA which does not inhibit NOS and is eliminated 
almost exclusively via the kidneys (Nijveldt et al. 2002).
Methods and materials
Study population
Adult RTR (n = 817) who were treated at the University 
Medical Center Groningen, The Netherlands, were invited 
to participate in the study between November 2008 and 
March 2011. The current study is part of a larger prospec-
tive cohort study of RTR in the North of the Netherlands 
(Transplantlines Food and Nutrition cohort, Clinicaltrials.
gov No NCT02811835). Inclusion criteria were a renal 
transplantation ≥ 1 year before inclusion and a functioning 
graft. Exclusion criteria were a history of alcohol or drug 
abuse, malignancy (other than cured skin cancer), overt con-
gestive heart failure (NYHA 3–4), and insufficient under-
standing of Dutch. Out of 817 RTR invited to participate, 
706 RTR signed a written informed consent. After exclud-
ing those without data on pADMA and uADMA, 685 RTR 
were included in the present study. Data on uSDMA were 
available in 673 RTR. Subjects were at steady state at all 
measurements, i.e., without acute illness and biochemically 
stable. The study was approved by the institutional ethical 
review board (METc 2008/186) and has been conducted in 
accordance with the declaration of Helsinki.
Clinical measurements
Blood was drawn after a fasting period of at least 8 h. Each 
participant collected 24-h urine according to instructions. 
Detailed descriptions of anthropomorphic measurements 
have been described before (van den Berg et al. 2012, 2013, 
2014). We performed the anthropomorphic measurements 
on the same day as blood collection. Body surface area 
(BSA) was calculated using the Du Bois–Du Bois formula 
(Du Bois and Du Bois 1916). Body mass index (BMI) was 
calculated as weight (kg) divided by squared height (meters). 
Smoking status and alcohol intake were measured by ques-
tionnaire. We categorized smoking as never, ex, or current. 
Alcohol intake was categorized as 0–10, 10–30, or > 30 g/
day.
Laboratory measurements
We measured pADMA, uADMA, and uSDMA with a 
validated GC–MS/MS method (Thermoquest TSQ 7000, 
Finnigan MAT, San Jose, California, USA) as described in 
detail earlier (Tsikas et al. 2003; Frenay et al. 2015; Bollen-
bach et al. 2018). Other urine and blood analyses have been 
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performed using routine laboratory methods as described 
earlier (van den Berg et al. 2012, 2013, 2014).
We calculated the estimated glomerular filtration rate 
(eGFR) using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula with serum creatinine and 
cystatin C. In a subset of the study population (n = 201), 
true GFR (measured GFR; mGFR) was measured by infu-
sion of low-dose 125I-iothalamate, as previously described 
(Apperloo et al. 1996). We defined proteinuria as a urinary 
excretion of ≥ 0.5 g/24 h.
Long‑term outcomes
Long-term outcomes were all-cause mortality, CVD mortal-
ity, and non-cardiovascular disease (non-CVD) mortality. 
CVD mortality was defined as death as a result of cardio-
vascular disease (ICD-9: 410–447): coronary artery disease, 
cerebrovascular accident, heart failure, and sudden death, as 
described before (National Center for Health Statistics 2011; 
Minović et al. 2017). The cause of death was retrieved from 
medical records or, if necessary, from correspondence with 
the RTR’s general practitioner or referring hospital.
Statistical analyses
We performed univariable linear regression analyses of 
pADMA, uADMA, and uSDMA with all basic character-
istics to study those which are associated with pADMA, 
uADMA, or uSDMA. Kaplan–Meier analyses were per-
formed for the associations of sex-adjusted tertiles of 
pADMA, uADMA, and uSDMA with outcomes and differ-
ences between tertiles tested by log-rank tests. We applied 
multivariable Cox regression analyses to study the associa-
tions of pADMA, uADMA, and uSDMA with outcomes. 
The proportionality of hazards assumption was tested with 
the Schoenfield residual test and was not violated for the 
associations of pADMA, uADMA, or uSDMA with all out-
comes (P > 0.05 for all analyses). To test the assumption for 
linearity, we applied restricted cubic splines (knots: mini-
mum, median, and maximum) for non-transformed variables 
and compared these with linear splines. Splines were fitted 
on a Cox model and adjusted for age, sex, BMI, eGFR, and 
proteinuria. We used two-sided Wald test for non-linearity 
analysis: P for non-linearity of the association of pADMA, 
uADMA, and uSDMA with all-cause, CVD, and non-CVD 
mortality was for all > 0.05. Partially, cumulative models 
were used to reduce the possibility of over-fitting for the Cox 
regression analyses: we adjusted for basic confounders (age, 
sex, BMI, eGFR, proteinuria) in model 1. We added other 
potential confounders to model 1 in all subsequent models. 
In the model 5, we adjusted the associations of pADMA 
with outcomes for uADMA (model 5a) and uSDMA (model 
5b), the associations of uADMA for pADMA (model 5) and 
uSDMA (model 5b), and the associations of uSDMA for 
pADMA (model 5) and uADMA (model 5a). In the final 
model, we adjusted the associations of pADMA, uADMA, 
and uSDMA for each other in a combined model. We per-
formed secondary analyses in a smaller subset of the study 
population (n = 201) who had data available on mGFR by 
low-dosage 125I-iothalamate, as described earlier (Apper-
loo et al. 1996), to study the association of muscle mass 
turnover, reflected by 24-h urinary creatinine excretion, and 
amino acid turnover, reflected by 24-h urinary urea excre-
tion, with pADMA, uADMA, and uSDMA. We also studied 
the effects of adjusting for urinary creatinine excretion and 
urea excretion in the associations of pADMA, uADMA, and 
uSDMA with mortality.
We tested for the interactions of pADMA, uADMA, 
uSDMA with each other, age, sex, BMI, eGFR, proteinuria, 
urinary creatinine excretion, and urinary urea excretion by 
adding an interaction-variable composed of the product of 
pADMA, uADMA, or uSDMA and the above-mentioned 
variables.
We performed analyses with IBM SPSS statistics ver-
sion 23 (2015, IBM corp., Armonk, NY, USA). Figures 
were made with GraphPad Prism version 5.04 for Windows 
(2010, GraphPad Software, La Jolla, California, USA) and 
R statistics version 3.2.3 (2015, R Foundation for Statistical 
Computing, Vienna, Austria). Normally distributed variables 
are presented as mean ± standard deviation (SD), skewed 
data as median [interquartile range (IQR)]. We regarded a P 
value of ≤ 0.05 as statistically significant.
Results
Bas ic  charac te r i s t i c s  o f  685  RTR a re  p re -
sented in Table  1. pADMA is 0.61 ± 0.12  µM, 
uADMA is 31.4 ± 13.2  µmol/24  h, and uSDMA is 
52.3 ± 19.1 µmol/24 h. The Pearson correlation between 
pADMA and uADMA is − 0.08, P = 0.04. Pearson cor-
relation of pADMA and uSDMA is − 0.09, P = 0.02. 
Pearson correlation of uADMA with uSDMA is 0.53, 
P < 0.001. High pADMA, uADMA, and uSDMA are 
associated with the male gender. High uADMA shows an 
opposite association pattern compared to pADMA with 
regard to its associations with less use of antihypertensive 
drugs, less history of CVD, more physical activity, higher 
urinary creatinine excretion, higher urinary urea excre-
tion, living donor transplantation, shorter cold ischemia 
time, immunosuppressive medication usage, and overall 
better renal function. Higher uADMA is also associated 
with larger weight, higher BMI and BSA, lower total and 
low-density lipoprotein cholesterol, lower triglycerides, 
lower C-reactive protein, lower N-terminal pro-brain 
natriuretic peptide, less diabetes as primary disease cause, 
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Table 1  Basic characteristics








St. β P St. β P St. β P
Number of participants 685 685 685 673
ADMA
 Plasma ADMA (µM) 0.61 ± 0.12 N/A − 0.08 0.04 − 0.09 0.02
 Urinary ADMA excretion (µmol/24 h) 31.4 ± 13.2 − 0.08 0.04 N/A 0.53 < 0.001
 Urinary SDMA excretion, (µmol/24 h) 52.3 ± 19.1 − 0.09 0.02 0.53 < 0.001 N/A
Demographics
 Age of patient (years) 54.7 [44.8–63.0] 0.12 0.001 − 0.05 0.16 − 0.07 0.08
 Male gender, n (%) 390 (56.9) 0.08 0.03 0.23 < 0.001 0.30 < 0.001
Body composition (recipient)
 Weight (kg) 80.4 ± 16.4 − 0.05 0.24 0.22 < 0.001 0.25 < 0.001
 BMI (kg/m2) 26.0 [23.2–29.3] − 0.05 0.23 0.12 0.002 0.08 0.04
 BSA  (m2) 1.94 ± 0.22 − 0.05 0.23 0.25 < 0.001 0.30 < 0.001
Cardiovascular parameters
 Systolic blood pressure (mmHg) 136 ± 17.4 0.03 0.50 − 0.02 0.67 0.06 0.16
 Diastolic blood pressure (mmHg) 82.5 ± 10.9 − 0.04 0.33 0.06 0.11 0.11 0.01
Number of antihypertensives, n (%)c
  0 antihypertensive drugs 79 (11.5) Ref Ref
  1 antihypertensive drugs 108 (27.4) 0.08 0.21 − 0.07 0.21 − 0.02 0.79
  ≥ 2 antihypertensive drugs 418 (61.0) 0.15 0.01  − 0.20 0.001 − 0.03 0.61
 NTpro-BNP (ng/L) 250 [106–625] 0.07 0.09 − 0.19 < 0.001 − 0.12 0.003
Cardiovascular disease history
 Myocardial infarction, n (%) 34 (5.0) 0.08 0.03 0.01 0.76 − 0.003 0.94
 CABG and/or PCI, n (%) 55 (8.0) 0.10 0.01 − 0.05 0.19 − 0.02 0.53
 CVA and/or TIA, n (%) 39 (5.7) − 0.04 0.31 − 0.08 0.04 − 0.03 0.41
Diabetes
 Diabetes n (%)a 162 (23.6) 0.08 0.05 − 0.04 0.29 − 0.04 0.29
 Glucose (mM) 5.2 [4.8–6.0] 0.06 0.15 0.02 0.57 − 0.04 0.36
 HbA1c (%) 5.8 [5.5–6.2] 0.02 0.71 0.03 0.48 − 0.03 0.40
Lipids
 Total cholesterol (mM) 5.13 ± 1.13 − 0.05 0.17 − 0.14 < 0.001 − 0.15 < 0.001
 HDL cholesterol (mM) 1.30 [1.10–1.60] − 0.14 < 0.001 0.02 0.62 − 0.06 0.13
 LDL cholesterol (mM) 2.90 [2.30–3.50] − 0.02 0.54 − 0.08 0.04 − 0.10 0.01
 Triglycerides (mM) 1.68 [1.25–2.30] 0.02 0.59 − 0.17 < 0.001 − 0.11 0.004
Inflammation
 CRP (mg/L) 1.6 [0.7–4.6] − 0.03 0.47 − 0.08 0.04 − 0.06 0.12
 Blood leukocyte (× 109/L) 8.1 ± 2.6 − 0.08 0.03 0.04 0.31 0.01 0.74
Smoking behavior, n (%)b
 Never 269 (39.3) Ref. Ref.
 Ex 293 (42.8) 0.01 0.79 − 0.02 0.57 − 0.01 0.88
 Current 82 (12.0) − 0.01 0.88 0.01 0.77 0.03 0.51
Alcohol intake, n (%)b
 0–10 g/24 h 459 (67.0) Ref. Ref
 10–30 g/24 h 136 (19.9) − 0.01 0.81 0.04 0.30 0.15 < 0.001
 > 30 g/24 h 29 (4.2) − 0.02 0.59 0.06 0.13 0.13 0.001
Physical activity (SQUASH score) 5070 [1970–8018] − 0.10 0.01 0.09 0.02 0.13 0.001
Urinary creatinine excretion (mmol/24 h) 11.6 ± 3.5 − 0.16 < 0.001 0.50 < 0.001 0.54 < 0.001
Urinary urea excretion (mmol/24 h) 388 ± 115 − 0.09 0.02 0.51 < 0.001 0.52 < 0.001
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ADMA asymmetric dimethylarginine, SDMA symmetric dimethylarginine, BMI body mass index, BSA body surface area, NT-proBNP N-termi-
nal pro-brain natriuretic peptide, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, CVA cerebrovascular accident, 
TIA transient ischemic attack, HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein, SQUASH short questionnaire 
to assess health enhancing physical activity, CNI calcineurin inhibitor, mTOR mammalian target of rapamycin, eGFR estimated glomerular filtra-
tion rate, mGFR measured glomerular filtration rate
a Defined as blood glucose ≥ 7 mM, HbA1c ≥ 6.5, and/or use of antidiabetics
b Percentages do not add up to 100% due to missing cases
c Percentages do not add up to 100% because of rounding
d Sirolimus or everolimus
e Reference is non-user
f Chronic kidney disease epidemiology collaboration (CKD-EPI) formula with creatinine-cystatin C
g Measured only in a smaller subset of 201 RTR 
Table 1  (continued)








St. β P St. β P St. β P
Pre-transplant disease, n (%)c
 Dysplasia and hypoplasia 28 (4.1) 0.01 0.78 0.02 0.71 0.05 0.23
 Glomerulonephritis 51 (7.4) − 0.04 0.32 − 0.03 0.56 0.04 0.41
 Diabetes mellitus 34 (5.0) 0.05 0.21 − 0.12 0.01 − 0.03 0.55
 Polycystic renal disease 142 (20.7) 0.04 0.44 − 0.07 0.19 0.03 0.55
 Primary glomerular disease 196 (28.6) − 0.03 0.58 − 0.04 0.50 0.10 0.07
 Renovascular disease 39 (5.7) − 0.004 0.93 − 0.06 0.19 0.09 0.04
 Tubular interstitial disease 79 (11.5) − 0.04 0.35 − 0.01 0.80 0.02 0.67
 Other/unknown cause 116 (16.9) Ref. Ref Ref
Time between transplantation and baseline (years) 5.39 [1.84–12.11] 0.04 0.25 − 0.10 0.01 − 0.12 0.002
Total dialysis time (months) 27 [9 – 51] 0.13 0.001 − 0.03 0.50 − 0.08 0.05
Living donor transplantation, n (%) 233 (34.0) − 0.12 0.002 0.09 0.02 0.11 0.01
Ischemia times
 Cold ischemia times (h) 15.4 [2.8–21.2] 0.11 0.004 − 0.11 0.004 − 0.10 0.01
 Warm ischemia times (min) 40 [34–50] 0.02 0.69 0.03 0.48 0.01 0.80
Rejection before baseline, n (%) 181 (26.4) 0.02 0.64 − 0.12 0.001 − 0.02 0.63
Number of transplantations, n (%)
 1 616 (89.9) Ref. Ref
 2 or more 69 (10.1) 0.07 0.09 − 0.09 0.02 − 0.10 0.01
Immunosuppressive medication
 Prednisolone dosage (mg/24 h) 10.0 [7.5–10.0] 0.06 0.15 0.10 0.01 0.11 0.003
 CNI usage n (%) 390 (56.9) 0.09 0.01 − 0.15 < 0.001 0.03 0.51
  Tacrolimus 119 (17.4) 0.09e 0.03 − 0.17e < 0.001 − 0.002e 0.96
  Cyclosporine A 272 (39.7) 0.08e 0.05 − 0.12e 0.002 0.03e 0.44
 Proliferation inhibitor usage n (%) 571 (83.4) − 0.10 0.01 0.09 0.02 0.06 0.12
  Mycophenolate mofetil 451 (65.8) − 0.14e 0.004 0.15e 0.002 0.11e 0.03
  Azathioprine 120 (17.5) − 0.06e 0.27 − 0.02e 0.72 − 0.04e 0.47
 mTOR inhibitor  usaged 20 (2.9) − 0.08 0.04 0.02 0.55 − 0.06 0.11
Renal allograft function
 Serum urea (mM) 9.6 [7.2–13.4] 0.23 < 0.001 − 0.65 < 0.001 − 0.23 < 0.001
 Serum creatinine (µM) 125 [99–162] 0.15 < 0.001 − 0.57 < 0.001 − 0.14 < 0.001
 eGFRf (mL/min/1.73 m2) 43.5 [30.6–58.0] − 0.31 < 0.001 0.72 < 0.001 0.25 < 0.001
 mGFRg (mL/min) 55.1 ± 20.5 − 0.30 < 0.001 0.77 < 0.001 0.32 < 0.001
 Protein excretion (g/24 h) 0.19 [0.02–0.37] 0.03 0.41 − 0.15 < 0.001 − 0.004 0.92
 Proteinuria (≥ 0.5 g per 24 h), n (%) 155 (22.6) 0.06 0.12 − 0.17 < 0.001 − 0.01 0.90
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shorter time between transplantation and baseline, less 
rejection before baseline, and lower number of previous 
transplantations. Higher pADMA is additionally associ-
ated with older age, lower blood leukocyte count, lower 
high-density lipoprotein cholesterol, more cases of diabe-
tes mellitus, and longer dialysis time. uSDMA shows an 
association pattern comparable to that of uADMA, except 
for alcohol intake with which uSDMA is associated and 
uADMA not, and calcineurin inhibitor use with which 
uSDMA is not associated, while uADMA is.
Associations with mortality
Out of 685 RTR, 147 died during median follow-up of 5.4 
[4.9–6.1] years. Of these, 58 (39%) died of CVD. There were 
more all-cause and non-CVD mortalities in the highest sex-
adjusted tertile of pADMA compared to the lower tertiles 
(Fig. 1). In contrast, there were less all-cause, CVD, and 
non-CVD mortalities in the highest sex-adjusted tertile of 
uADMA and uSDMA compared to lower tertiles (Fig. 1). 
Figure 2 illustrates linear splines in which the distribution 
of pADMA, uADMA, and uSDMA is plotted against the 
hazard ratio of the respective variables for their associa-
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Fig. 1  Associations of sex-adjusted tertiles of plasma ADMA 
(pADMA), urinary ADMA excretion (uADMA), and urinary SDMA 
excretion (uSDMA) with all-cause mortality, cardiovascular (CVD) 
mortality, and non-cardiovascular (non-CVD) mortality. Median 
[range] in µM per tertile of pADMA: tertile 1: 0.50 [0.31–0.57]; ter-
tile 2: 0.61 [0.54–0.66]; tertile 3: 0.72 [0.64–1.12]. Median [range] 
in µmol/24  h per tertile of uADMA: tertile 1: 18.8 [3.1–26.9]; ter-
tile 2: 30.2 [22.0–39.1]; tertile 3: 43.7 [32.2–97.4]. Median [range] in 
umol/24 h per tertile of uSDMA: tertile 1: 35.3 [7.08–48.7]; tertile 2: 
50.3 [38.5–63.5]; tertile 3: 67.9 [49.8–191.6]
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mortality (fitted by a Cox regression model, adjusted for age, 
sex, BMI, eGFR, and proteinuria).
In Table 2, Cox regression analyses of pADMA, uADMA, 
and uSDMA with outcomes are presented. Univariably, 
pADMA is strongly associated with all-cause mortality (HR 
per SD [95% CI]: 1.45 [1.26–1.67], P < 0.001), CVD mortal-
ity (HR per SD [95% CI]: 1.30 [1.03–1.65], P = 0.03), and 
non-CVD mortality (HR per SD [95% CI]: 1.55 [1.30–1.84], 
P < 0.001). Conversely, uADMA is inversely associated with 
all-cause mortality (HR per SD [95% CI]: 0.57 [0.47–0.69], 
P < 0.001), CVD mortality (HR per SD [95% CI]: 0.55 
[0.40–0.74], P < 0.001), and non-CVD mortality (HR per SD 
[95% CI]: 0.59 [0.46–0.75], P < 0.001). Similar to uADMA, 
uSDMA is inversely associated with all-cause mortality (HR 
per SD [95% CI]: 0.67 [0.55–0.82], P < 0.001), CVD mortal-
ity (HR per SD [95% CI]: 0.63 [0.46–0.87], P = 0.01), and 
non-CVD mortality [HR per SD [95% CI]: 0.70 [0.55–0.91], 
P = 0.01). The associations of pADMA with all-cause 
mortality and non-CVD mortality, and the associations of 
uADMA and uSDMA with all-cause mortality and CVD 
mortality are independent of age, sex, eGFR, and potential 
confounders such as CVD risk factors and transplantation-
related factors. The HR of the associations of uADMA with 
outcomes remained relatively stable when adjusted for con-
founders (models 1–4), while the associations of pADMA 
with outcomes became considerably weaker.
In interaction analyses, we found a weak but significant 
interaction of pADMA with the presence of proteinuria 
(P = 0.02). The univariable association of pADMA with all-
cause mortality is stronger in RTR without proteinuria com-
pared to those with proteinuria (events and HR per SD [95% 
CI]: 94 events and 1.54 [1.30–1.82] vs. 53 events and 1.22 






























































































































































































































































































































Fig. 2  Linear splines of the associations of plasma ADMA 
(pADMA), urinary ADMA excretion (uADMA), and urinary SDMA 
excretion (uSDMA) with all-cause mortality, cardiovascular disease 
(CVD) mortality, and non-CVD mortality. Data were fit by a Cox 
proportional hazard model for all splines and adjusted for age, sex, 
body mass index, proteinuria, and estimated glomerular filtration rate 
(chronic kidney disease epidemiology collaboration formula with cre-
atinine–cystatin C). The hazard ratio is represented by the black line, 
the 95% confidence interval by the gray area
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Table 2  Association of plasma ADMA and urinary excretions of ADMA and SDMA with all-cause mortality, cardiovascular mortality, and non-
cardiovascular mortality
pADMA plasma asymmetric dimethylarginine, uADMA urinary asymmetric dimethylarginine excretion (24  h), uSDMA urinary symmetric 
dimethylarginine excretion (24 h), BMI body mass index, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, CVA cerebro-
vascular accident, TIA transient ischemic attack, CNI calcineurin-inhibitor, mTOR mammalian target of rapamycin
a eGFR was calculated according to the Chronic Kidney Disease Epidemiology formula with serum creatinine and plasma cystatin C
pADMA uADMA uSDMA
All-cause HR per SD [95% CI] P HR per SD [95% CI] P HR per SD [95% CI] P
 Crude 1.45 [1.26–1.67] < 0.001 0.57 [0.47–0.69] < 0.001 0.67 [0.55–0.82] < 0.001
 Model 1 1.29 [1.09–1.52] 0.004 0.67 [0.49–0.91] 0.011 0.76 [0.62–0.93] 0.01
 Model 2 1.21 [1.01–1.46] 0.04 0.58 [0.41–0.83] 0.002 0.66 [0.53–0.82] < 0.001
 Model 3 1.24 [1.04–1.49] 0.02 0.64 [0.47–0.88] 0.01 0.78 [0.63–0.96] 0.02
 Model 4 1.27 [1.07–1.50] 0.01 0.66 [0.48–0.90] 0.01 0.79 [0.65–0.97] 0.02
 Model 5 n/a 0.60 [0.44–0.82] 0.001 0.76 [0.62–0.93] 0.01
 Model 5a 1.36 [1.15–1.62] < 0.001 n/a 0.82 [0.65–1.03] 0.09
 Model 5b 1.27 [1.07–1.51] 0.01 0.79 [0.55–1.13] 0.20 n/a
 Model 6 1.33 [1.12–1.58] 0.001 0.69 [0.48–0.99] 0.04 0.86 [0.68–1.08] 0.19
Cardiovascular
 Crude 1.30 [1.03–1.65] 0.03 0.55 [0.40–0.74] < 0.001 0.63 [0.46–0.87] 0.01
 Model 1 1.09 [0.82–1.45] 0.54 0.54 [0.33–0.89] 0.02 0.65 [0.46–0.90] 0.01
 Model 2 0.97 [0.72–1.32] 0.86 0.53 [0.30–0.92] 0.03 0.59 [0.42–0.83] 0.002
 Model 3 1.03 [0.77–1.38] 0.83 0.53 [0.32–0.87] 0.01 0.67 [0.48–0.93] 0.02
 Model 4 1.08 [0.81–1.43] 0.60 0.54 [0.32–0.90] 0.02 0.67 [0.48–0.93] 0.02
 Model 5 n/a 0.52 [0.31–0.85] 0.01 0.65 [0.47–0.90] 0.01
 Model 5a 1.18 [0.89–1.56] 0.25 n/a 0.71 [0.49–1.04] 0.08
 Model 5b 1.10 [0.83–1.46] 0.51 0.74 [0.42–1.31] 0.30 n/a
 Model 6 1.15 [0.86–1.54] 0.34 0.70 [0.39–1.24] 0.22 0.73 [0.50–1.06] 0.10
Non-cardiovascular
 Crude 1.55 [1.30–1.84] < 0.001 0.59 [0.46–0.75] < 0.001 0.70 [0.55–0.91] 0.01
 Model 1 1.42 [1.15–1.75] 0.001 0.77 [0.52–1.14] 0.19 0.85 [0.66–1.09] 0.19
 Model 2 1.39 [1.10–1.74] 0.01 0.63 [0.41–0.98] 0.04 0.72 [0.54–0.96] 0.02
 Model 3 1.39 [1.10–1.76] 0.01 0.73 [0.48–1.10] 0.13 0.87 [0.67–1.15] 0.33
 Model 4 1.39 [1.13–1.72] 0.002 0.75 [0.50–1.13] 0.17 0.88 [0.68–1.12] 0.29
 Model 5 n/a 0.67 [0.45–0.99] 0.04 0.85 [0.66–1.09] 0.21
 Model 5a 1.49 [1.20–1.84] < 0.001 n/a 0.90 [0.67–1.19] 0.45
 Model 5b 1.39 [1.12–1.72] 0.003 0.83 [0.53–1.31] 0.43 n/a
 Model 6 1.45 [1.17–1.81] 0.001 0.69 [0.44–1.09] 0.11 0.95 [0.72–1.26] 0.74
Model 1 Crude + basic confounders (age, sex, BMI,  eGFRa, proteinuria)
Model 2 Model 1 + Framingham Risk Score factors (total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive 
treatment, smoking (current, ex, or never), diabetes), medical history of coronary intervention, medical history of myocar-
dial infarction, and medical history of CVA and/or TIA
Model 3 Model 1 + transplantation-related factors (donor type, total dialysis time, time from transplantation to baseline, cold 
ischemia time, CNI usage, proliferation inhibitor usage, mTOR inhibitor usage, and number of transplantations up to 
baseline)
Model 4 Model 1 + primary disease
Model 5 Model 1 + pADMA
Model 5a Model 1 + uADMA
Model 5b Model 1 + uSDMA
Model 6 Model 1 + uSDMA, uADMA, and pADMA combined
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[0.96–1.56], respectively). Furthermore, there is a weak, but 
significant interaction of uSDMA with age for the associa-
tion with non-CVD mortality (P = 0.01). The univariable 
association of uSDMA with non-CVD mortality is stronger 
for RTR with age above the median of 55 years compared 
to those with age equal to or below the median (events and 
HR per SD [95% CI]: 70 events and 0.66 [0.50–0.88] vs. 17 
events and 1.14 [0.67–1.94], respectively).
Model fit
Although models with uADMA had comparable or slightly 
better fit for all-cause and CVD mortality, there is no sig-
nificant difference in Harrell C statistic (Supplementary 
Table S1). For non-CVD mortality, pADMA has a slightly 
better fit, but the difference is not statistically significant. 
When both uADMA and pADMA are included in the same 
model, the associations of both pADMA and uADMA with 
outcomes not only remain significant, but become stronger 
(Table 2, model 5). Also, the association of uADMA with 
non-CVD mortality in the combined model remains inde-
pendent of adjustment for potential confounders. There is a 
significant improvement in Harrell C statistics and − 2 log 
likelihood for the combined pADMA and uADMA model 
vs. the single pADMA model for the unadjusted association 
with all-cause mortality (Supplementary Table S2: Harrell 
C: P = 0.03; − 2 log likelihood: P < 0.001). When adjusted 
for age, sex, BMI, eGFR, and proteinuria, the difference for 
Harrell C statistics is lost (P = 0.27), while it remains signifi-
cant for the − 2 log likelihood (P = 0.001). For the associa-
tion with CVD mortality, there is no significant improve-
ment of model fit according to the Harrell-C statistic when 
both pADMA and uADMA are included in the model. Yet 
there is an improvement for the model fit of pADMA when 
combined with uADMA according to the − 2 log likelihood 
(P < 0.001 and P = 0.01 for unadjusted and adjusted models, 
respectively). For the association with non-CVD mortality, 
there is only a significant improvement in fit according to 
the Harrell-C statistic for the combined model in compari-
son with uADMA alone (P = 0.04). However, according to 
the − 2 log likelihood, the model fit of both pADMA and 
uADMA for the association with non-CVD improves when 
they are combined.
Associations with muscle and amino acid turnover 
markers
In secondary analyses, we studied the associations of urinary 
creatinine and urea excretion with pADMA, uADMA, and 
uSDMA in a smaller subset of RTR who had mGFR data 
(n = 201). There are strongly positive and significant asso-
ciations of urinary creatinine excretion and urea excretion 
with uADMA and uSDMA (Table 3), independent of age, 
sex, BMI, proteinuria, use of mammalian target of rapamy-
cin (mTOR) inhibitors and mGFR (creatinine: st. β: 0.27, 
P < 0.001; urea: st. β: 0.30, P < 0.001). Urinary creatinine 
is also (negatively) associated with pADMA, while urinary 
urea excretion is not associated with pADMA (Table 3; st. 
β: − 0.20, P = 0.03 and st. β: − 0.02, P = 0.81, respectively).
In further analyses, we adjusted the associations of 
pADMA, uADMA, and uSDMA with long-term outcomes 
for urinary creatinine excretion and urinary urea excre-
tion (Table 4). The associations of pADMA, uADMA, and 
uSDMA with all-cause mortality and CVD mortality are 
highly dependent upon urinary creatinine excretion: the 
increased risk of pADMA with all-cause and non-CVD 
mortality is reduced by a third, while the associations of 
uADMA and uSDMA with all-cause and CVD mortality are 
lost. Similar to urinary creatinine excretion, but to a lesser 
extent, the association of pADMA with all-cause mortality 
is also dependent upon 24-h urinary urea excretion.
There are significant interactions between urinary cre-
atinine and urea excretion with uADMA for the association 
with CVD mortality (interaction coefficients with uADMA: 
urinary creatinine: 0.07, P = 0.01; urinary urea: 0.07, 
P = 0.01). There is no significant interaction coefficient of 
uADMA, uSDMA or pADMA with urinary creatinine or 
urea excretion for the associations with all-cause and non-
CVD mortality.
Discussion
To our knowledge, we have shown for the first time an 
inverse association of uADMA and of uSDMA with all-
cause and CVD mortality in a large, prospective cohort study 
of RTR. Unadjusted, there is a risk reduction of 43%, 45%, 
and 41% per standard deviation increment of uADMA for 
all-cause, CVD, and non-CVD mortality, respectively. The 
associations with all-cause and CVD mortality are independ-
ent of adjustment for potential confounders. Results for anal-
yses with uSDMA were comparable to those for uADMA. 
pADMA was associated with an increase in all-cause and 
non-CVD mortality, but not with CVD mortality. In second-
ary analyses, we have found that pADMA, uADMA, and 
uSDMA are strongly and independently associated with 
urinary creatinine excretion. Additionally, uADMA and 
uSDMA are strongly associated with urinary urea excretion. 
The associations of uADMA and uSDMA with all-cause, 
CVD, and non-CVD mortality are highly dependent upon 
urinary creatinine excretion and urinary urea excretion.
The mean pADMA concentration in the RTR popula-
tion of our study is comparable to that of the general public 
(Atzler et al. 2014). The association of pADMA with CVD 
and renal outcomes has been demonstrated in the literature 
in CKD patients and the general population (Zoccali et al. 
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Table 3  Associations of urinary creatinine and urea excretions with plasma ADMA and urinary excretions of ADMA and SDMA in a subpopu-
lation of RTR (n = 201)
pADMA plasma asymmetric dimethylarginine, uADMA urinary asymmetric dimethylarginine excretion (24  h), uSDMA urinary symmetric 
dimethylarginine excretion (24 h), mTOR mammalian target of rapamycin, mGFR measured GFR (by 125I-iothalamate)
Dependent pADMA
Predictor Urinary creatinine excretion Urinary urea excretion
St.β P St.β P
Crude − 0.21 0.003 − 0.10 0.14
Model 1 − 0.30 0.001 − 0.12 0.11
Model 2 − 0.20 0.03 − 0.02 0.81
Dependent uADMA
Predictor Urinary creatinine excretion Urinary urea excretion
St.β P St.β P
Crude 0.49 < 0.001 0.56 < 0.001
Model 1 0.55 < 0.001 0.52 < 0.001
Model 2 0.27 < 0.001 0.30 < 0.001
Dependent uSDMA
Predictor Urinary creatinine excretion Urinary urea excretion
St.β P St.β P
Crude 0.52 < 0.001 0.47 < 0.001
Model 1 0.36 < 0.001 0.41 < 0.001
Model 2 0.29 < 0.001 0.34 < 0.001
Model 1 Crude + age, sex, BMI, proteinuria, and use of mTOR inhibitors
Model 2 Model 1 + mGFR
Table 4  Effect of urinary 
creatinine and urea excretion 
on the associations of plasma 
ADMA and urinary excretions 




pADMA plasma asymmetric dimethylarginine, uADMA urinary asymmetric dimethylarginine excretion 
(24 h), uSDMA urinary symmetric dimethylarginine excretion (24 h), BMI body mass index, eGFR esti-
mated glomerular filtration rate, mTOR mammalian target of rapamycin
a eGFR was calculated according to the Chronic Kidney Disease Epidemiology formula with serum creati-
nine and plasma cystatin C
pADMA uADMA uSDMA
HR per SD [95% CI] P HR per SD [95% CI] P HR per SD [95% CI] P
All-cause
 Base 1.30 [1.10–1.55] 0.002 0.68 [0.50–0.92] 0.01 0.77 [0.62–0.94] 0.01
 Model 1 1.19 [1.01–1.42] 0.04 1.14 [0.81–1.60] 0.46 0.98 [0.80–1.21] 0.87
 Model 2 1.26 [1.06–1.49] 0.01 0.97 [0.69–1.36] 0.87 0.94 [0.75–1.17] 0.55
Cardiovascular
 Base 1.10 [0.83–1.46] 0.52 0.54 [0.33–0.89] 0.02 0.65 [0.47–0.90] 0.01
 Model 1 1.00 [0.75–1.33] 0.99 0.87 [0.50–1.51] 0.62 0.81 [0.57–1.16] 0.25
 Model 2 1.06 [0.80–1.42] 0.69 0.69 [0.39–1.20] 0.19 0.73 [0.50–1.05] 0.09
Non-cardiovascular
 Base 1.45 [1.17–1.79] 0.001 0.78 [0.53–1.17] 0.23 0.86 [0.66–1.11] 0.23
 Model 1 1.33 [1.07–1.65] 0.01 1.37 [0.89–2.12] 0.15 1.10 [0.87–1.41] 0.43
 Model 2 1.39 [1.12–1.72] 0.003 1.22 [0.79–1.87] 0.37 1.09 [0.84–1.42] 0.51
Base Crude + age, sex, BMI,  eGFRa, proteinuria, and use of mTOR inhibitors
Model 1 Base + 24 h urinary creatinine excretion
Model 2 Base + 24 h urinary urea excretion
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2001; Achan et al. 2003; Fliser et al. 2005), but we are the 
first to present the associations between uADMA and long-
term outcomes. For the RTR population, we revealed earlier 
in the same cohort the association between higher pADMA 
and all-cause mortality with a shorter follow-up (median 
3.1 vs. 5.4 years) (Frenay et al. 2015). In the present study, 
we have demonstrated that uADMA is a more consistent 
predictor of mortality compared to pADMA, with hazard 
ratio remaining relatively stable when adjusted for potential 
confounders, while the hazard ratio for pADMA fluctuates 
more depending on the adjustment. Furthermore, we have 
shown that pADMA and uADMA strengthen each other’s 
association with long-term outcomes when put together in 
a statistical model. This may be explained by an inverse 
collinearity, where pADMA is dependent upon the abil-
ity to be renally excreted; pADMA increases as uADMA 
decreases. Then, one may suggest that we may be looking 
at the effect of renal ADMA clearance and thereby renal 
function rather than the individual effects of pADMA and 
uADMA in the presented models. The importance of kidney 
function in the homeostasis of circulatory ADMA has been 
emphasized repeatedly in the literature, as several studies 
have observed that pADMA increases with worsening renal 
function. However, the reality is far more complex since only 
a fraction of about 17% of exogenous circulating ADMA 
(intravenous injection of 3 mg/kg) is excreted unchanged 
in the urine (Achan et al. 2003). The remainder is largely 
metabolized by dimethylarginine dimethylaminohydrolase 
(DDAH) to citrulline and dimethylamine (DMA), with the 
latter being excreted in the urine (Achan et al. 2003). A 
small portion of ADMA is transaminated by the mitochon-
drial aminotransferase alanine-glyoxylate aminotransferase 
2 (AGXT2) to α-keto-δ-(NG, NG-dimethylguanidino) valeric 
acid (Rodionov et al. 2010; Morris 2016). Diminished activ-
ity of DDAH and AGXT2 has been suggested as the main 
reason of pADMA accumulation in the blood rather than 
lower renal clearance (Matsuguma et al. 2006; Kayacelebi 
et al. 2015). We have recently published a study in kidney 
donors that demonstrated an acute renal function impair-
ment resulting from kidney donation drastically reduced the 
urinary excretion of ADMA, but had a minimal effect on 
plasma ADMA (Said et al. 2019).
Being an NOS inhibitor, pADMA has been traditionally 
associated with cardiovascular outcomes (Kielstein and 
Zoccali 2005). We found that not pADMA, but uADMA 
is strongly associated with CVD mortality in RTR. Simi-
larly, Böger et al. (2009) found no significant association of 
pADMA with cardiovascular death in 3320 normal subjects 
from the Framingham Offspring Study (Böger et al. 2009). 
Wolf et al. (2012) found that a high ADMA/creatinine con-
centration in spot urine samples was strongly protective 
against cardiac death in a cardiovascular risk population 
(Wolf et al. 2012). The findings of Böger et al. and Wolf 
et al. corroborate our findings. Furthermore, we have dem-
onstrated that the associations revealed for uSDMA closely 
resemble those for uADMA. uSDMA is known to be almost 
exclusively eliminated by renal excretion (Nijveldt et al. 
2002). While only ADMA can be metabolized by DDAH, 
both ADMA and SDMA can be metabolized by AGXT2. 
Recently, AGXT2 activity has been found to be associated 
with worse clinical outcomes in CKD patients (Martens-
Lobenhoffer et al. 2018). It had been suggested that higher 
AGXT2 activity may be a response to elevated systemic 
ADMA and SDMA levels, possibly due to decreased renal 
excretion. In the current study, given that the associations 
of uSDMA and uADMA are closely alike and significant 
despite adjustment for renal function, it is possible that 
variation in AGXT2 activity is the driving force underlying 
the found associations. It would suggest that high AGXT2 
(and thereby low uADMA and low uSDMA) would indeed 
be associated with worse outcomes. The underlying patho-
physiology remains speculative, however. So far, uSDMA 
has not been found to have significant direct NO-inhibitory 
properties. However, it has been suggested that uSDMA can 
compete with l-arginine transport, having an indirect inhibi-
tory property (Bode-Böger et al. 2006).
The production of ADMA and SDMA depends on two 
subsequent steps of post-translational arginine methylation 
mediated by a family of methyltransferases [protein argi-
nine methyltransferases (PRMTs)]. Of these, nine PRMTs 
have been implicated in catalyzing the first step of arginine 
residue methylation to monomethylated arginine (MMA) 
in mammalian cells (Blanc and Richard 2017). Based on 
the ability to catalyze a subsequent methylation step, the 
PRMTs can be subdivided in three types. Type 1 PRMTs 
are represented by six members of the methyltransferase 
family (PRMT1–4, 6, 8) and generate ADMA, while type 
2 PRMTs are represented by two members of the methyl-
transferase family (PRMT5, 9) and generate SDMA (Tang 
et al. 1998; Branscombe et al. 2001; Frankel et al. 2002; 
Lee et al. 2005; Zurita-Lopez et al. 2012; Dhar et al. 2013; 
Yang et al. 2015; Cura et al. 2017; Shishkova et al. 2017). 
Type 3 PRMTs are represented by a single member of the 
methyltransferase family (PRMT7) and do not catalyze a 
subsequent methylation step (Zurita-Lopez et al. 2012)), 
which causes them to only produce MMA and thus far only 
histones are known substrates for this enzyme (Feng et al. 
2013; Blanc and Richard 2017). In general, virtually all 
types of cell are capable of producing ADMA, presumably 
because ADMA originates from the turnover of arginine-
methylated proteins, which are apparently present in all 
cell types (Teerlink 2005). In this respect, we attempted to 
study the associations between ADMA, and urinary cre-
atinine and urea excretion. In biochemically stable condi-
tions, urinary creatinine excretion measured in 24-h urine 
is accepted as a reflection of total body muscle mass (Wyss 
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and Kaddurah-Daouk 2000). Creatinine is produced from 
the likely irreversible, non-enzymatic dehydration of cre-
atine, which is necessary for the phosphocreatine buffer of 
the cellular energy provision (Wyss and Kaddurah-Daouk 
2000). Muscular tissue provides by far most of body creatine 
from the turnover of muscle proteins (Hunter 1922; Wyss 
and Kaddurah-Daouk 2000); a high 24-h urinary creatinine 
excretion in stable conditions implies a large muscle pro-
tein turnover resulting from larger muscle mass (Heyms-
field et al. 1983). Therefore, urinary creatinine excretion may 
reflect the production of ADMA from muscle protein turno-
ver too, as represented by the positive association of urinary 
creatinine excretion with uADMA. Alternatively, it may be 
that muscle mass maintenance is dependent upon ADMA 
homeostasis, although this has scarcely been studied. The 
negative and weaker association of pADMA with urinary 
creatinine excretion may be explained due to this mecha-
nism. Muscle synthesis is mediated by the activation of the 
protein kinase B-mTOR (Schiaffino et al. 2013). One of the 
pathways that activate mTOR is by triggering neuronal NOS 
(nNOS) (Ito et al. 2013). ADMA is a universal NOS inhibi-
tor and a strong inhibitor of nNOS activity (Kielstein et al. 
2007), which may then negatively affect muscle growth. 
Ito et al. (2013) performed a study in nNOS-null mice and 
showed that nNOS-null mice not only had less muscle mass 
increase in response to load stimulation compared to wild-
type mice, but that the administration of NG-nitro-l-arginine 
methyl ester (l-NAME), an exogenous inhibitor of all NOS 
isoforms, prevented an increase in muscle mass in wild-type 
mice (Ito et al. 2013). Wild-type mice that were adminis-
tered the enantiomer d-NAME, which does not inhibit NOS 
activity, did increase in muscle mass. Frandsen et al. (2001) 
have studied l-NAME infusion in six healthy young men and 
found a 67% lower NOS activity in skeletal muscle biopsies 
after infusion compared to control biopsies (Frandsen et al. 
2001). However, whether an acute inhibition of NOS activity 
will have a noticeable acute effect on muscle mass is ques-
tionable. To our knowledge, no studies have been performed 
in human participants that have studied the effects of NOS 
inhibition on muscle mass. We found a very strong positive 
association of urinary creatinine excretion with uADMA and 
a negative association with pADMA, independent of age, 
sex, BMI, proteinuria, mTOR inhibitors, and mGFR in a 
smaller subset of our study population. It is likely that both 
mechanisms of the interaction of muscle mass and ADMA 
play a role, possibly leaning more to the side of muscle mass 
being a source of ADMA since the positive association of 
urinary creatinine excretion with uADMA is much stronger 
than the negative association with pADMA. Last, the nega-
tive association between pADMA and urinary creatinine 
excretion may be due to residual confounding and promotes 
the need for further research into the interplay between 
pADMA and creatinine excretion.
In the current study, urinary urea excretion was strongly 
associated with uADMA, but not with pADMA. That urea 
excretion is more likely a nutritional marker than an amino 
acid turnover marker may partly explain this. Urea is pro-
duced from ammonia in amino acid metabolism and 24-h 
urinary urea excretion may be viewed as a marker of not only 
amino acid turnover, but also average dietary protein intake 
and thereby a reflection of an independent dietary ADMA 
source itself (Weiner et al. 2015). pADMA is relatively inde-
pendent of nutritional intake, as demonstrated by the study 
of Schneider et al. (2015), who found that daily oral arginine 
supplementation (9.96 g/24 h) had little effect on pADMA 
concentration after 3 months in patients with peripheral 
occlusive artery disease and after 6 months in patients with 
coronary artery disease compared to placebo (Schneider 
et al. 2015). This may be due to increased compensatory 
ADMA metabolism and/or due to increased elimination via 
the renal route. Therefore, uADMA may be more reflec-
tive of dietary ADMA intake than pADMA. Furthermore, 
it is important to remember that dietary protein, reflected by 
urinary urea excretion, is also a substrate for muscle protein 
synthesis, and urea excretion has been strongly correlated to 
muscle mass before (Said et al. 2015). Therefore, urea excre-
tion may be similarly reflective of ADMA production from 
muscle protein turnover. When the associations of uADMA 
and pADMA with mortality are adjusted for creatinine 
and urea excretion, the associations become considerably 
weaker. We hypothesize, therefore, that muscle turnover 
and protein intake play a significant role in the production, 
homeostasis, and pathogenesis of ADMA.
Strengths of the present study are the large study pop-
ulation and the long follow-up. The prospective study 
design and the large variety of measured variables ena-
bled us to adjust for many confounding risk factors at 
baseline. A limitation of this study is that the exact origin 
of pADMA or uADMA is unknown. It may be possible 
that urinary ADMA excretion reflects more renal ADMA 
production rather than systemic ADMA production. The 
strong, independent associations with urinary creatinine 
and urea excretion, and parameters reflecting systemic 
ADMA sources are in favor of the theory that pADMA 
and uADMA reflect systemic homeostasis, although fur-
ther studies are needed to independently assess specific 
renal ADMA production and provide clarity. Nevertheless, 
the results of this study are relevant as they demonstrate 
that uADMA is not only a strongly significant, but also 
a more consistent predictor of long-term outcomes than 
pADMA. It would have been interesting to study how 
plasma SDMA would compare to pADMA. A potential 
role for arginine methylation in cardiovascular disease 
largely remained indirect via the inhibition of endogenous 
NO synthase in endothelial cells by MMA and ADMA 
(Stühlinger et al. 2001; Peng and Wong 2017), but recent 
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evidence also suggests a more direct role. It has, for 
example, been found that arginine methylation mediated 
by PRMT3 and PRMT5 regulates the expression of the 
cardiac voltage-gated sodium channel  Nav1.5, which may 
be implicated in the development of heart failure (Beltran-
Alvarez et al. 2013, 2014). Inclusion of plasma SDMA 
data complemented by urinary SDMA excretion data, in 
addition to plasma ADMA data complemented by urinary 
ADMA excretion data, might also have given information 
on the balance between activities of type 1 and type 2 
PRMTs. However, for the current study it was not possible 
to measure SDMA in plasma, since the applied method of 
GC–MS/MS does not allow for accurate measurement of 
SDMA in plasma. Although GC–MS/MS provides a reli-
able and accurate method to measure plasma and urinary 
ADMA (Tsikas et al. 2003), and has recently been dem-
onstrated to be also suitable for measuring urinary SDMA 
(Bollenbach et al. 2018), it is not suitable for measurement 
of plasma SDMA (personal communication).
A further limitation is that our study was observational 
in nature, which makes that the associations unveiled do not 
necessarily imply causation.
In conclusion, high uADMA and high uSDMA are 
associated with lower risk of all-cause mortality and less 
cardiovascular mortality in RTR. Higher muscle mass and 
protein intake are associated with lower pADMA levels and 
higher uADMA and uSDMA excretion. The association of 
pADMA, uADMA, and uSDMA with long-term outcomes 
in RTR is also highly dependent on markers of muscle mass 
and protein intake. Our results suggest that an increase in 
muscle mass and amino acid turnover is associated with 
a beneficial increase in uADMA without an increase in 
pADMA, even when adjusted for renal function. The exact 
mechanism of these associations needs further clarification 
in future studies. However, our data present opportunities to 
influence the negative effects of ADMA through potentially 
modifiable factors, namely muscle mass and dietary pro-
tein intake. An intervention involving the modification of 
muscle mass and dietary protein intake, and their influence 
on ADMA and SDMA homeostasis is warranted. Clinical 
implications of this study may be to stimulate muscle mass 
growth, possibly by increased protein intake and physical 
activity, to augment ADMA and SDMA excretion and to 
reduce risk of premature mortality.
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